Evaluation of Safety of Acellular Dermal Matrix(ADM) in Breast Reconstruction

Outline: The total number of study subjects is 120, with 60 people recruited prospectively into the test group and 60 people retrospectively into the control group. The test group will receive SC Derm Recon(ADM processed by CO2 supercritical fluid technology) during the implant-based breast reconstruction surgery. The control group will be retrospectively and consecutively selected from medical records of patients who underwent implant breast reconstruction using ADM from other companies between March 1, 2021, and March 31, 2024. After surgery, patients will be followed up at 2 weeks, 4 weeks, and 12 weeks. Primary Objectives I. To assess whether the test group with applying the ADM processed by the supercritical fluid technology will have less short-term major complications than the control group with the ADM processed by detergents.